riordan clinic I.V Vitamin Therapy Clinc

High-Dose Vitamin C Infusions

We have been providing high-dose vitamin C infusions for over a decade, collaborating closely with the Riordan Clinic Research Medical Team. Our staff adheres to strict IV protocols and is specially trained in Intravenous Vitamin C administration. We source our vitamin C from corn-free, preservative-free alternatives. Inspired by the owner's journey through Stage 4 blood cancer and his subsequent remission, we are dedicated to supporting patients in their healing process with intravenous vitamins.

IV High-Dose Vitamin C Options:
7,000 MG/7 Grams: $99.00
15,000 MG/15 Grams: $150.00
25,000 MG/25 Grams: $200.00
50,000 MG/50 Grams: $250.00
75,000 MG/75 Grams: $300.00

Add-Ons:
- Glutathione + B-complex + Totalcobalmin infused separately: $95.00 (500ML LR infused after High Dose Vitamin C)

IV Vitamin C Packages:
7,000mg: 5 for $475.00 - 10 for $900.00
15,000mg: 5 for $700.00 - 10 for $1300.00
25,000mg: 5 for $950.00 - 10 for $1700.00
50,000mg: 5 for $1200.00 - 10 for $2200.00
75,000mg: 5 for $1400.00 - 10 for $2500.00

Benefits Include:
Strengthening the immune system
Supporting cancer treatment
Alleviating symptoms of Lyme disease, colds, flu, and allergies
Reducing muscle aches and fatigue
Enhancing skin rejuvenation and organ cleansing
Boosting hydration and replenishing essential nutrients
Detoxifying the body and decreasing inflammation

Our primary focus is utilizing high-dose Intravenous Vitamin C (IVC) to address various health conditions, providing hope and support for those facing long-term illnesses. Extensive medical research backs the efficacy of IV Vitamin C Therapy, highlighting its role as a powerful antiviral agent and its ability to enhance immune response. Our infusions ensure the highest quality of vitamin C, using non-corn-based, pesticide-free products.

Note on Packages:
IV Vitamin Packages are non-transferable and must be used by the designated patient, who must present ID at treatment. No returns are allowed after the first IV is administered from a package.

Vitamin C and Cancer: Antitumor Activity of Sodium Ascorbate Therapy The Center had been already using intravenous Vitamin C clinically when we began our research. Dr. Hugh Riordan’s vision of treating and preventing ailments with a non-toxic nutritional approach led him to become one of the first doctors to use IV vitamin C as a treatment protocol in patients with terminal cancers. This vision led to original research at the clinic, as well as numerous articles, patents, a series of IVC symposiums, and health initiatives. Dr. Riordan first became aware of this therapy in the early 1980’s, when a 70-year old patient suffering from metastatic renal cell carcinoma that had spread to his liver and lungs came to the clinic requesting IV ascorbate infusions. The patient had read Pauling’s research, and Dr. Riordan was the only doctor in Wichita using IV vitamin C. Upon his request, he began IV vitamin C treatment, starting at 30 grams twice per week. Fifteen months after initial therapy, the patient’s oncologist reported that the patient had no signs of progressive cancer. The patient remained cancer-free for 14 years. Based on his experience, Dr. Riordan set a goal for a cancer research project devoted to finding of the non-toxic cancer treatment. The Riordan Clinic has treated hundreds of cancer patients using the Riordan protocol. At the same time, Riordan Clinic Research Institute has been researching the potential of intravenous vitamin C therapy for over thirty years. Our efforts have included in vitro studies, animal studies, pharmacokinetic analyses, and clinical trials. The group validated the use of the IV vitamin C for cancer therapy. Using in vitro studies, more than 60 cell lines were tested for the toxicity to high dosages of ascorbate. It was demonstrated that at a high enough dose ascorbate can kill cancer cells while not affecting normal cells. In addition, it was found that IVC treatment improves the quality of life of advanced cancer patients, corrects deficiencies of vitamin C that often occur in cancer patients and optimizes white blood cell concentrations of vitamin C. Analysis of the markers of inflammation in cancer patients showed that high dose intravenous ascorbic acid treatment reduces inflammation in cancer patients. Several of these successful cases were published in the Journal of Orthomolecular Medicine. Three of these cases were reviewed by the NIH years later, confirming the presence of cancer and the benefit of treatment. Intravenously administered vitamin C as cancer therapy: three cases. Padayatty S, Riordan H, Hewitt S, Katz A, Hoffer L, Levine M. Canadian Medical Association Journal, 2006, 174(7):937-942 One of our early research achievements was to demonstrate that ascorbate is preferentially toxic to cancer cells at concentrations achievable during intravenous infusions. We also learned that cytotoxicity can be enhanced by other agents, such as lipoic acid, and magnetic fields. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Riordan N, Riordan H, Meng X, Li Y, Jackson J. Medical Hypotheses, 1995, 44(3):207-213 Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Casciari J, Riordan N, Schmidt T, Meng X, Jackson J, Riordan H. British Journal of Cancer, 2001, 84(11):1544-1550 The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells. Mikirova N, Jackson J, Casciari, Riordan H. Orthomolecular Medicine, 2001, 16(3):177-182 We demonstrated that ascorbate administration in guinea pigs reduced tumor growth rates, and that intra-tumor concentrations in the millimolar range were attained. This information, along with data on plasma ascorbate concentrations achievable in humans intravenously, allows us to set a recommended target dose per infusion. Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. Casciari J, Riordan H et al. Puero Rico Health Sciences Journal, 2005, 24(2):145-150 Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. Mikirova NA, Casciari JJ, Riordan NH and Hunninghake RE. Journal of Translational Medicine, 2013, 11:191 (Aug 2013). In addition to the aforementioned case studies, we have published analysis of ascorbate pharmacokinetics (plasma concentration rise and fall after infusion) and a Phase I clinical study. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. Riordan H, Casciari J, Gonzalez M, Riordan N, Miranda-Massari J, Jackson J. Puero Rico Health Sciences Journal, 2005, 24(4):269-276 Work on high dose vitamin C and cancer continued with detailed studies of how vitamin C affects new blood vessel growth (angiogenesis). Since angiogenesis is a key stage in tumor growth, its inhibition by vitamin C may provide a mechanism for anti-cancer effect. Anti-angiogenic effect of high doses of ascorbic acid. Mikirova N, Ichim T, Riordan N. Journal of Translational Medicine, 2008, 6:50 Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. Mikirova NA, Casciari JJ, Riordan NH. Journal of Angiogenesis Research 2010, 2:2 These, along with studies by outside collaborators, confirm the following: therapeutic concentrations of ascorbate can be achieved intravenously; ascorbate therapy appears safe and does not adversely affect renal function; ascorbate has anti-tumor activity and ascorbate does not interfere with the action of chemotherapeutic agents.

Study of Vitamin C Pharmacology The intravenous administration of high dose ascorbate (IVC) has increased in popularity among complementary and alternative medicine practitioners: thousands of patients received IVC, at an average dose of 0.5 g/kg, without significant side effects. While IVC may have a variety of possible applications, it has generated the most interest for its potential use in treating cancer. To continue our efforts to find properties of Vitamin C in enhancement of patient well-being, we studied its pharmacology in cancer patients. Using our cancer patient database, we analyzed vitamin C absorption in cancer patients before and after IVC therapy. Our results support the theory that cancer patients are deficient in vitamin C, and that tumors and other tissues act as vitamin C “sinks”, so that extra IVC treatments are needed in order to replenish depleted stores: For a given dose of IVC, cancer patients, on average, achieved lower plasma ascorbate increases compared to healthy adults. Among cancer patients, subjects with lower pre-treatment serum ascorbate levels tend to show less of a serum level increase post IVC. In cancer patients, subjects who had metastatic tumor burdens showed significantly lower plasma ascorbate levels post-IVC as compared to subjects who had primary tumors but no metastases. Cancer patients with elevated levels of the inflammation marker CRP tended to have lower serum ascorbate levels pre-treatment and post-IVC. Plasma ascorbate levels post-IVC in cancer patients were lower in patients with higher levels of tumor markers. The results of the study were published in a peer-reviewed journals: Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. Mikirova NA, Casciari JJ, Riordan NH and Hunninghake RE. Journal of Translational Medicine, 2013, 11:191 (Aug 2013). Intravenous ascorbic acid protocol for cancer patients: scientific rationale, pharmacology, and clinical experience. Mikirova NA, Casciari JJ Hunninghake RE, Riordan NH. Functional Foods in Health and Disease 2013; 3(8):344-366 High dose intravenous ascorbic acid on suppression of inflammation in patients with cancer and rheumatoid arthritis. Inflammation represents a series of biological responses of immune cells and vascular tissues to harmful stimuli such infection or inflammation. Acute inflammation refers to the early stage immune system response to an injury: vascular permeability increases to allow elevated blood flow and white blood cell migration to the site. This in turn leads to acute reactions such as redness, swelling, and temperature increase. White blood cells activation also leads to increased production of inflammatory cytokines such as interleukin one (IL-1), interleukin six (IL-6) and tumor necrosis factor alpha (TNF-α). If the injury persists, however, the inflammation response can become chronic. This leads to a situation where white blood cells such as macrophages continue producing cytokines and, while continuing their attack on foreign microbes, release reactive oxygen species (ROS) and other chemicals that harm normal tissue. Chronic inflammation is thought to be involved in the progression of several sustained illnesses, including rheumatoid arthritis, asthma, irritable bowel syndrome, atherosclerosis, diabetes, and cancer. Inflammation plays a key role in tumor development, affecting tumor proliferation, angiogenesis, metastasis, and resistance to therapy. Key features of cancer-related inflammation (CRI) include leukocyte infiltration, cytokine build-up, tissue remodelling, and angiogenesis. Infiltrating leukocytes such as tumor associated macrophages (TAMs), neutrophils, dendritic cells, and lymphocytes establish an inflammatory microenvironment and are key components in tumors of epithelial origins. In clinical studies, TAMs are associated with poor prognosis, while the use of anti-inflammatory agents is associated with reduced instances of certain cancers. Several studies indicate that inflammation is a marker of high cancer risk and poor treatment outcome. In response to systemic inflammation, and in particular in response to elevated IL-6 levels, the liver produces (C-reactive protein) CRP, a protein that binds to dead or dying cells to activate the complement system. This led to our interest in what clinical markers of chronic inflammation are available, how do these markers correlate with disease status, and how to therapies commonly used at the Riordan Clinic, intravenous vitamin C (IVC) therapy, for example, affect inflammation. Our inflammation research began with a study of our patient history database to determine how inflammation markers such as CRP correlate with cancer markers and how they changed during IVC. IVC therapy was associated decreases in cancer markers as well as decreases in CRP and in pro-inflammatory cytokines (interleukins 1, 2, and 8, as well as interferon-gamma). Since inflammation is associated with poor cancer prognosis, this was an important finding. Our clinical data supported the hypothesis that high dose intravenous ascorbate treatments may reduce inflammation in cancer patients. We published our results in a peer-reviewed journal: Effect of high-dose intravenous vitamin C on inflammation in cancer patients Mikirova NA, Casciari JJ, Taylor PR and Rogers AM Journal of Translational Medicine, 2012, 10:189 (Sep 2012) Intravenous ascorbic acid to prevent and treat cancer-associated sepsis. Ichim TE, Minev B, Braciak T, Luna B, Hunninghake R, Mikirova NA, Jackson JA, et al. Journal of Translational Medicine 2011, 9:25 Later we conducted a similar analysis based on patients who had rheumatoid arthritis and were treated with IVC. Rheumatoid arthritis (RA) is a major inflammatory joint disease that causes cartilage destruction, bone erosions, and joint destruction. Oxidative stress is elevated in RA patients implying reactive oxygen species (ROS) are possible mediators of tissue damage. ROS trigger a cascade of events through nuclear factors’ activation (NF-kappa B), which up-regulates gene expression of pro-inflammatory cytokines that mediate the immune responses causing inflammation. As ascorbic acid can reduce oxidative stress, decrease production of pro-inflammatory cytokines, and suppress the activation of NF-kappa B, we suggest that millimolar concentration of ascorbic acid may be useful in RA treatment. In our study we analyzed the effect of intravenous vitamin C (IVC) treatment on subjects with RA. Our data suggested that IVC therapy with dosages of 7.5 g – 50 g can reduce inflammation. The level of inflammation as measured by C-reactive protein levels was decreased on average by 44%. Based on our pilot study, we hypothesize that IVC therapy can be a useful strategy in treating RA Some of our key findings: CRP levels in arthritis patients correlate with weight and fat content: obesity was associated with inflammation in these subjects. CRP reductions with IVC therapy were more dramatic when the treatments were given more frequently. We published our results in a peer-reviewed journal: Effect of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis Mikirova NA, Rogers AM, Casciari JJ, Taylor PR Modern Research in Inflammation, 2012, 1(2):26-32 (Nov 2012)

Cancer and Immunology Our research team’s first area of intense focus was in the treatment of cancer. Our efforts to devise treatments for cancer that work with the body instead of against it included biological response modifiers to stimulate immune response, ex vivo cultivation and anti-cancer antigen training of dendritic cells, tumor angiogenesis (blood vessel growth) inhibition, and the use of intravenous vitamin C (along with lipoic acid, in some cases) as a “gentle” anti-cancer agent and adjuvant. Our interest in immunotherapy began with our dendritic cell research in the late 1990s. Under Dr. Neil Riordan’s supervision, we developed techniques for isolating dendritic cells from whole blood and “training” them to respond to tumor antigens. The technology we developed was eventually licensed to a private firm. In addition we analyzed the white blood cell bio-energetics in healthy and ill subjects by measuring mitochondrial potentials and ATP levels of whole blood lymphocytes and granulocytes. These assays were as diagnostic tools or as outcome metrics for immunotherapy. The results of our studies were published in journals: Assessment of granulocyte activity with application to healthy and ill subjects. Mikirova N, Riordan H, Klykov A. Orthomolecular Medicine, 2002, 17(3):151-161 Monitoring of ATP levels in red blood cells and T cells of healthy and ill subjects and the effects of age on mitochondrial potential. Mikirova N, Riordan H, Kirby K, Klykov A, Jackson J. Orthomolecular Medicine, 2005, 20(1):50-58 Granulocyte activity in patients with cancer and healthy subjects. Mikirova N, Klykov A, Jackson J, Riordan N. Cancer Biology and Therapy, 2008, 7(9):41-46 As vitamin C is thought to be vital for the maintenance of proper immune system functioning, we studied if and how vitamin C supplementation correlates with immune cell performance in white blood cells collected from healthy adults. Specifically, the ability of phagocytes to digest bacteria, the ability of lymphocytes to proliferate in response to PHA, the ability of monocytes to develop into mature antigen trained dendritic cells, and the ability of dendritic cell trained lymphocytes to lyse tumor cells were determined ex vivo. Phagocytic index, lymphocyte proliferation index, and mature dendritic cell yields (from monocytes) all decreased with donor age in a statistically significant fashion. However, once the effect of donor age is accounted for, immune cell performance was superior in cells from donors who supplemented with at least 1 g per day of vitamin C. The addition of 5 to 20 mg/dL sodium ascorbate to the growth medium during ex vivo assays improved the ability of phagocytes to digest bacteria and increased the tumor cell killing capabilities of dendritic cell trained lymphocytes. Effect of Vitamin C Supplementation on Ex Vivo Immune Cell Functioning. Joseph J. Casciari, Hugh D. Riordan, Nina Mikirova, Jan Austin. JOM, 18, 2, 2003.

High Dose IV Vitamin C (IVC) Making health a journey, not a destination. A foundational treatment provided at the Riordan Clinic is the use of high-dose Intravenous Vitamin C (IVC) to treat a wide variety of conditions and promote wellness. Our approach provides help and hope to individuals struggling with a long-term illness, while focusing on getting and staying healthy, rather than only addressing symptoms. There are many conditions that may benefit from IVC therapy. Arthritis, Lyme disease, bacterial infections, viral infections, pain after injury, and more. There is a great deal of medical research to support the use of IV Vitamin C therapy. It is one of the best antiviral agents available, with the ability to neutralize and eliminate a wide range of toxins. Vitamin C will enhance host resistance, greatly augmenting the immune system’s ability to neutralize bacterial and fungal infections. The Riordan Clinic Research Team has decades of studies, internationally published articles and has sent speakers worldwide sharing this research with doctors. The National Institutes of Health has published evidence confirming Vitamin C’s anti-cancer properties. We have found that when cancer patients receive IV Vitamin C they report a reduction in their pain level and they are better able to tolerate chemotherapy. Intravenous Vitamin C is complementary to oncologic care, so patients may continue their conventional cancer therapies if they choose to. To download an informative description of “IV Vitamin C for Cancer Care”, please click HERE. IV Vitamin C Therapy Benefits Lessens pain after injuries Helps the body heal faster Improves energy levels/fatigue Resiliency to infections like colds/flu or other viral/bacterial infections In cancer patients, IVC is known to improve the response to cancer therapies because it alleviates the effects of traditional therapies, improves appetite and helps patients remain more active With rising concerns regarding the purity and sources of the foods in our diets, it is also important to be aware of the nutrients sourced for your daily vitamins, IVs, and injections. Our staff is constantly working with vendors to make sure that we offer only the highest quality services and nutrients for our co-learners. Resources Continuous Intravenous Vitamin C in the Cancer Treatment: Reevaluation of a Phase I Clinical Study (2019) Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate cancer Suppression of Alkaline Phosphatase in Prostate Cancer Patients by High Dose Intravenous Vitamin C Treatment: Three Cases High-Dose Intravenous Vitamin C Treatment of a Child with Neurofibromatosis Type 1 and Optic Pathway Glioma: A Case Report [VIEW MORE ARTICLES] [VIEW RESEARCH STUDIES] Learn More Are you a doctor or medical professional wanting to learn more about using IV Vitamin C in your practice? The Riordan Clinic hosts an IVC Symposium and IVC Academy as an opportunity to learn from experts in our field. Find out more at: IVCandCancer.org